Study You Wish to Participate - None -Iron and Folic acid supplimentation and adverse birth outcomes in BotswanaThe Botswana Epidemiological ART Treatment Cohort Study 2 (2TheBEAT Cohort Study) Botswana Safe Birth StudyIncreasing Access to Multiple Micronutrient Supplementation – A Pilot Intervention at up to 15 Clinics in Botswana Evaluating Opportunities to Improve TB and HIV Care for Adolescents in BotswanaPoint-of-Care HIV Testing and Early Dolutegravir Use for InfantsImproving TB Screening in Pregnant and Postpartum Women Living with HIV in BotswanaAssessment of Proviral Reservoir: Synergistic combination of reporter cell assay and viral diversityP1093 - Phase I/II, Multi-Centre, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsA Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)/ Tatelo StudyIMPAACT 2019 – Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of AgeIMPAACT 2005IMPAACT 2017 - Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and AdolescentsHVTN805/HPTN093: Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081.PHOENIx (A5300B): Protecting Households on Exposure to Newly Diagnosed Index Multidrug Resistant TB patientsREPRIEVE (A5332): A randomized trial to prevent vascular events (such as stroke and heart attack) in people living with HIV.HVTN 703/HPTN 081 (AMP Study): A phase 2b study to evaluate the efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in Sub- Saharan Africa.CoVPN 5001: A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection.Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern: CoVPN 3008Open-Label, Single-Arm, Phase 3B Study of the Incidence of Severe COVID-19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenInternational Sexual Health and Reproductive (ISHARE) Health Survey During COVID-19Understanding the Mechanisms of Adverse Birth Outcomes in BotswanaSOLIDARITY Trial: An international (multisite)randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careA cross-sectional evaluation of antibody responses to SARS-COV-2 vaccinesIntegrating Hypertension and Cardiovascular Diseases Care into Existing HIV Services Package in Botswana (InterCARE Study)HIV and Malignancy in Botswana: An observational Study of Medicine Toxicity of Concurrent Treatment and Clinical Outcomes (Thabatse Study)Exploring the Acceptability and Feasibility of COVID19 Testing among Truck Drivers in BotswanaCharacterization of Anthracycline induced Cardiotoxicity Using Cardiac Magnetic Resonance in Botswana: A Prospective Observational study (Pelo Study)Feasibility and Accuracy of Nanosenor-based cancer diagnosis at the point of care (Chedza Study).Prevalence and outcomes of the usage of lumbar puncture in patients who presented with central nervous system symptoms at Princess Marina Hospital during the period 01/01/2014 to 31/03/2021Mitigating the impact of COVID-19 effects in adolescent reproductive health through self-testing: a mixed methods pilot study: “ICHEKE”Open-label access to dolutegravir for HIV-1 infected children and adolescents completing IMPAACT Studies P1093 and P2019: GSK205858Post-acute sequelae of SARS-CoV-2 infection (PASC) / ‘Long Covid’: observational cohort: “Motlhala” StudyNeurodevelopment In HEU Children Exposed In Utero To Dolutegravir or Efavirenz and HIV-Unexposed Children (Motheo Study)Innovative HIV Testing Strategy for Middle-to-Upper Income Men in a Resource-Limited SettingThe diagnosis and treatment of Chlamydia Trachomatis and Neisseria Gonorrhea in Woman to prevent adverse neonatal consequences (Maduo/STI Study)Contraceptives and Dolutegravir-based ART (CODA) StudyHuman Papillomavirus (HPV) Cervical Cancer Screening StudyBirth Outcomes Surveillance Study: Tsepamo StudyKarabo Study: Immune Correlates of Tuberculosis and non-Tuberculosis Infectious Morbidity in Southern African HIV- Exposed, Uninfected InfantsTshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV- Exposed Uninfected in BotswanaPotlako+ : A multilevel intervention to improve timely cancer detection and treatment initiation in BotswanaFLOURISH: Following Longitudinal Outcomes to Understand, Report, Intervene and Sustain Health for Infants, Children, Adolescents who are HIV Exposed UninfectedEarly Infant Treatment Study: A Clinical Trial of HIV Positive Infants in BotswanaMopati: A Pilot HIV Treatment Partner Intervention in BotswanaAlbuminuria Among Virally Suppressed HIV-infected Patients in Botswana: Longitudinal Changes and Association with Inflammation and ACEI/ARB Use in a Clinical Setting - Albuminuria StudyAssessing barriers and facilitators to improving prenatal supplementation and preconception fortification in Botswana – a qualitative study
